

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Assistant Editor:** Kirsty Strawbridge**Content Development Manager:** Joanna Aldred**Journal Manager:** Basil Nyaku**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

32 Jamestown Road, London, NW1 7BY, UK

Tel: +44 (0)20 7424 4200

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *ACT LLC and Collaborations in Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong, Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Melior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Pfizer Global Biologics, St. Louis, USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica, China***Pradeep Nathan** *Experimental Medicine, GSK and University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd. USA***Janice Reichert** *Tufts Center for the Study of Drug Development, USA***John Reidhaar-Olson** *Hoffmann-La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute, USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston, USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

EDITORIAL

173 Many are called, yet few are chosen. Are neuropsychiatric clinical trials letting us down?

Robert McArthur

PERSPECTIVE

FEATURE

176 Mitochondrial pharma-Q-genomics: Targeting the OXPHOS cytochrome *b*

Aurora Gómez-Durán, David Pacheu-Grau, Manuel J. López-Pérez, Julio Montoya and Eduardo Ruiz-Pesini

181 Exploiting personalized information for reagent selection in drug design

Jonas Boström, Niklas Falk and Christian Tyrchan

MONITOR

278 The design and synthesis of libraries for the discovery of antibacterial and antifungal substances

Paul John Edwards

280 DIARY

FORTHCOMING ARTICLES:

Supramolecular devices to improve the treatment of brain diseases

By Donatella Paolino, Donato Cosco, Roberto Molinaro, Christian Celia and Massimo Fresta

Target mTOR kinase domain: the second generation of mTOR inhibitors

By Yan-Jie Zhang, Yanwen Duan and X. F. Steven Zheng

How to compute genes for drug resistance dynamics

By Yunqian Guo, Jiangtao Luo, Jianxin Wang, Yaqun Wang and Rongling Wu

Nanonization strategies for poorly water-soluble drugs

By Huabing Chen, Chalermchai Khemtong, Xiangliang Yang, Xuelling Chang and Jinming Gao